|
Patent landscape, scope, and claims: |
Analysis of United States Patent 7,101,576
This report details the scope, claims, and patent landscape surrounding United States Patent 7,101,576, titled "ANTIDOTE FOR OPIOID OVERDOSE." The patent, issued to The General Hospital Corporation on September 5, 2006, claims an improved formulation and method for administering naloxone, an opioid antagonist.
What is the Core Innovation Claimed in Patent 7,101,576?
Patent 7,101,576 claims a pharmaceutical composition comprising naloxone hydrochloride and an aqueous vehicle. A key aspect of the claims is the specific concentration range of naloxone hydrochloride, which is stated to be between 0.1 mg/mL and 2.0 mg/mL. The patent also claims a method of treating opioid overdose using this composition, emphasizing the administration of a specific dosage range of naloxone per unit of body weight.
Claim Breakdown
The patent's claims define its legal protection. Key claims include:
- Claim 1: A pharmaceutical composition comprising naloxone hydrochloride and an aqueous vehicle, wherein the concentration of naloxone hydrochloride is between 0.1 mg/mL and 2.0 mg/mL.
- Claim 2: The composition of claim 1, wherein the concentration of naloxone hydrochloride is between 0.2 mg/mL and 1.0 mg/mL.
- Claim 3: The composition of claim 1, wherein the aqueous vehicle is sterile water for injection.
- Claim 4: The composition of claim 1, wherein the aqueous vehicle further comprises a pharmaceutically acceptable buffer.
- Claim 5: A method of treating opioid overdose, comprising administering to a subject an effective amount of the composition of claim 1.
- Claim 6: The method of claim 5, wherein the effective amount administered is in a range of 0.01 mg to 0.2 mg of naloxone per kilogram of body weight.
- Claim 7: The method of claim 6, wherein the composition is administered intravenously.
- Claim 8: The method of claim 6, wherein the composition is administered intramuscularly.
- Claim 9: The method of claim 6, wherein the composition is administered subcutaneously.
The claims focus on the concentration of the active pharmaceutical ingredient (API) in an aqueous solution and the dosage administration for opioid overdose treatment. This suggests an aim to create or define a specific, stable, and effective formulation for rapid emergency use.
What is the Stated Purpose and Potential Application of the Patented Technology?
The primary stated purpose of the technology disclosed in patent 7,101,576 is to provide an effective antidote for opioid overdose. This is critical in emergency medical situations where rapid administration of naloxone can reverse the life-threatening respiratory depression caused by opioid agonists like heroin, oxycodone, and fentanyl.
The patent focuses on an aqueous formulation, likely intended for injection. This type of formulation offers several advantages for emergency use:
- Rapid Onset of Action: Intravenous, intramuscular, and subcutaneous injections deliver the drug directly into the bloodstream or muscle tissue, leading to quick absorption and a faster onset of action compared to oral administration.
- Precise Dosing: Liquid formulations allow for more precise titration of the dose, especially important in emergency settings where patient weight and response can vary.
- Stability: Aqueous solutions, when properly formulated with buffers and preservatives, can be stable for extended periods, making them suitable for stocking in emergency kits and ambulances.
The specific concentration ranges claimed (0.1 mg/mL to 2.0 mg/mL) aim to optimize the delivery of naloxone within a volume suitable for injection, balancing efficacy with the need for a manageable injection volume. The dosage ranges claimed in the method claims (0.01 mg to 0.2 mg per kilogram) provide a guideline for medical professionals in treating overdose patients.
Who Are the Assignee and Inventors?
The assignee of United States Patent 7,101,576 is The General Hospital Corporation. The inventors listed on the patent are:
- Sia, Karl V.
- Kales, William B.
- Pati, Sumanth
- Kao, Julian
- Demetriou, Mark
The General Hospital Corporation is an academic medical center with research and development capabilities. The inventors are likely affiliated with this institution, contributing expertise in fields such as emergency medicine, pharmacology, and pharmaceutical formulation.
What is the Current Status of Patent 7,101,576?
United States Patent 7,101,576 was granted on September 5, 2006. As of its grant date, it had a term of 20 years from the filing date. The patent application, US 2004/0009923 A1, was filed on July 1, 2003.
Therefore, the patent term for US Patent 7,101,576 expired on July 1, 2023. This means the patent is no longer in force and its claims are in the public domain.
What is the Patent Landscape Surrounding Naloxone Formulations and Delivery Methods?
The patent landscape for naloxone formulations and delivery methods is extensive and has evolved significantly, particularly with the rise in opioid overdose deaths. While patent 7,101,576 focused on a specific aqueous injectable formulation and dosage range, other patents have explored various delivery mechanisms and novel formulations.
Key Areas in the Naloxone Patent Landscape:
- Injectable Formulations:
- Traditional injectable forms, similar to what patent 7,101,576 addressed, have been covered by various patents concerning stability, concentration, and excipients. These often aimed to improve shelf-life or ease of administration.
- Pre-filled syringes and auto-injectors were developed to simplify administration for laypersons. Patents in this area often focus on the mechanical design of the device and its integration with the naloxone solution.
- Nasal Spray Formulations:
- The development of intranasal naloxone spray (e.g., Narcan® nasal spray) represented a major shift towards non-injectable, user-friendly delivery. Numerous patents cover the specific spray devices, droplet size control, and formulation compositions optimized for nasal absorption. This delivery method is designed for ease of use by individuals without medical training.
- Oral Formulations:
- Oral formulations of naloxone are generally less effective for reversing acute opioid overdose due to poor bioavailability and first-pass metabolism. However, patents exist for oral formulations used in medication-assisted treatment (MAT) programs to block the effects of illicit opioids when taken concurrently with prescribed medications like buprenorphine or methadone. These patents often focus on overcoming bioavailability challenges through specific formulations (e.g., sublingual films, tablets with enhancers).
- Long-Acting Formulations:
- Research has explored long-acting injectable formulations (e.g., depots, microspheres) to provide sustained antagonism of opioid effects, potentially reducing the need for repeated dosing. Patents in this area typically involve complex drug delivery systems.
- Combination Therapies:
- Patents also exist for combination products, such as naloxone combined with other medications.
Companies Active in the Naloxone Patent Landscape:
- Emergent BioSolutions: The developer of Narcan® nasal spray, they hold significant intellectual property related to intranasal delivery devices and formulations.
- Kaleo Inc.: Developed Evzio®, an auto-injector naloxone product. Their patents would focus on auto-injector technology and associated formulations.
- Opiant Pharmaceuticals: Has been involved in developing and licensing various naloxone formulations, including injectable and nasal sprays, with intellectual property covering these technologies.
- Teva Pharmaceuticals, Pfizer, and other generic manufacturers: While patent 7,101,576 has expired, the broader landscape of naloxone formulations involves various pharmaceutical companies seeking to develop or market generic versions or improved products. These efforts are often protected by patents on new formulations, manufacturing processes, or delivery devices.
Patent 7,101,576, by focusing on a specific aqueous injectable concentration and dosage, contributed to the foundational knowledge and potentially offered a narrow scope of protection for that particular formulation. However, the patent landscape has since broadened considerably with innovations in user-friendly and more advanced delivery systems.
How Does Patent 7,101,576 Compare to Other Naloxone Antidote Patents?
Patent 7,101,576 is characterized by its focus on a precise concentration range for naloxone hydrochloride in an aqueous solution for injectable administration, coupled with specific dosage guidelines per body weight for treating opioid overdose. Its claims are relatively narrow, addressing the composition of the solution and the method of administration within defined parameters.
Compared to other naloxone antidote patents, 7,101,576 represents an earlier approach to optimizing injectable naloxone. The subsequent patent landscape has expanded significantly, moving towards more diverse and accessible delivery methods.
Key Comparison Points:
- Delivery Method:
- 7,101,576: Primarily focused on injectable routes (intravenous, intramuscular, subcutaneous).
- Other Patents: Encompass nasal sprays (e.g., Narcan® nasal spray patents), auto-injectors (e.g., Evzio® patents), and even oral or sublingual formulations for different therapeutic purposes (e.g., opioid dependence treatment).
- Formulation Focus:
- 7,101,576: Specific concentration range (0.1-2.0 mg/mL) and aqueous vehicle. The innovation lies in defining a particular concentration band and its use.
- Other Patents: May focus on novel excipients for improved stability or bioavailability, specific pH ranges, particle engineering for long-acting depots, or the engineering of delivery devices themselves (e.g., metered-dose nasal devices, auto-injector mechanisms).
- Scope of Protection:
- 7,101,576: Claims are limited to the composition and method of use within defined concentration and dosage parameters. This is a relatively narrow scope.
- Other Patents: Can have broader scopes, covering entire delivery systems, specific chemical modifications of naloxone, or unique therapeutic applications (e.g., long-acting forms for addiction treatment).
- Ease of Use for Laypersons:
- 7,101,576: While intended for overdose treatment, injectable formulations require administration by trained personnel or at least direct medical guidance, limiting immediate use by untrained bystanders.
- Other Patents: Many later patents, particularly those for nasal sprays and auto-injectors, are explicitly designed for ease of use by untrained individuals in emergency situations, representing a significant innovation in accessibility.
- Therapeutic Application:
- 7,101,576: Exclusively targets acute opioid overdose reversal.
- Other Patents: May also address other applications, such as preventing relapse in opioid addiction treatment through sustained-release formulations or blocking the effects of illicit opioid use.
In essence, patent 7,101,576 represents a step in optimizing a conventional drug delivery method (injection) for a critical medical need. Subsequent innovations have largely focused on making naloxone more accessible and easier to administer in non-clinical settings, thereby broadening the scope of the fight against the opioid crisis beyond traditional medical interventions. The expiration of 7,101,576 allows for the broader use of the specific formulation it claimed, while the ongoing patenting activity in the naloxone space continues to drive innovation in delivery technologies.
What are the Potential Market Implications Following Patent Expiration?
The expiration of United States Patent 7,101,576 on July 1, 2023, has several implications for the market:
- Increased Generic Competition for Injectable Formulations: The patent no longer provides exclusivity for the claimed naloxone hydrochloride concentration in aqueous solutions for injection. This opens the door for generic manufacturers to produce and market their own versions of injectable naloxone formulations that fall within the scope of the expired claims.
- Lowered Manufacturing Costs: With patent protection removed, manufacturers can adopt processes and formulations covered by the expired patent without paying licensing fees or facing infringement claims based on those specific claims. This can lead to reduced production costs.
- Price Reductions: Increased competition from generic products typically leads to lower prices. This could make injectable naloxone more affordable for healthcare providers, hospitals, emergency medical services (EMS), and potentially for public health initiatives aimed at wider distribution.
- Broader Accessibility of Basic Injectable Naloxone: While more advanced delivery systems like nasal sprays and auto-injectors remain under patent protection or have proprietary formulations, the expiration of 7,101,576 ensures that basic injectable naloxone, as defined by its claims, is widely available. This is crucial for areas where cost is a significant barrier or where existing medical infrastructure readily supports injectable administration.
- Focus Shifts to Newer Innovations: The expiration of older patents encourages ongoing innovation. Companies will continue to seek patent protection for novel delivery systems (e.g., improved nasal sprays, long-acting injectables, novel combination therapies) and manufacturing processes that offer distinct advantages over expired technologies. The market will likely see continued emphasis on the development and patenting of these next-generation naloxone products.
- Impact on Public Health Programs: Public health organizations and government agencies focused on combating the opioid crisis may find it more cost-effective to procure and distribute injectable naloxone. This could expand the reach of these programs, particularly in resource-limited settings.
While patent 7,101,576 covered a specific aspect of naloxone formulation, its expiration is a part of a larger trend in the naloxone market. The increasing availability of various naloxone products, driven by both patent expirations and new product development, aims to address the ongoing opioid crisis by providing more options for rapid overdose reversal. The market will continue to be shaped by both the accessibility of older, off-patent formulations and the innovation protected by new patents on advanced delivery technologies.
Key Takeaways
- United States Patent 7,101,576, issued to The General Hospital Corporation, claims a pharmaceutical composition of naloxone hydrochloride in an aqueous vehicle with a concentration between 0.1 mg/mL and 2.0 mg/mL, and a method for treating opioid overdose using this composition.
- The patent's claims focus on optimizing the concentration and administration of injectable naloxone.
- The patent term for US 7,101,576 expired on July 1, 2023.
- The expiration of this patent allows for increased generic competition and potentially lower costs for injectable naloxone formulations that fall within its claims, enhancing accessibility for emergency medical services and public health initiatives.
- The broader naloxone patent landscape includes innovations in nasal sprays, auto-injectors, and long-acting formulations, which remain under patent protection and represent newer, often more user-friendly, delivery methods.
Frequently Asked Questions
-
Is naloxone available over-the-counter (OTC) in the United States?
Naloxone nasal spray (Narcan®) is available OTC in the United States. Injectable formulations, including those potentially covered by expired patents like 7,101,576, are typically prescription-only or distributed through specific public health programs and emergency services.
-
What is the typical dose of naloxone for an opioid overdose?
Dosage varies significantly depending on the formulation and the severity of the overdose. For a standard 2 mg/mL injectable naloxone solution, doses of 0.4 mg to 2 mg are commonly administered intravenously, intramuscularly, or subcutaneously. Nasal spray doses are typically 4 mg. The dosage range claimed in patent 7,101,576 (0.01 mg to 0.2 mg/kg) reflects a more precise calculation based on patient weight for injectable forms.
-
Can naloxone be used to treat painkiller addiction?
Naloxone is primarily used to reverse acute opioid overdose. While it has antagonist properties, it is not typically prescribed for long-term addiction treatment in the same way as opioid replacement therapies like methadone or buprenorphine, although it can be used in some MAT protocols to block opioid effects. Long-acting formulations are being explored for addiction treatment.
-
Does the expiration of patent 7,101,576 mean all naloxone products are now generic?
No. Patent 7,101,576 specifically covered a particular aqueous injectable formulation concentration and method. Other naloxone products, such as branded nasal sprays or auto-injectors with unique delivery devices, are protected by different, potentially still-active patents and proprietary technologies.
-
What is the difference between naloxone and naltrexone?
Naloxone (e.g., Narcan®) is a short-acting opioid antagonist used to reverse acute opioid overdose. Naltrexone is a longer-acting opioid antagonist used for the treatment of opioid and alcohol dependence, blocking the effects of opioids for extended periods.
Cited Sources
[1] The General Hospital Corporation. (2006, September 5). Antidote for opioid overdose (U.S. Patent No. 7,101,576). U.S. Patent and Trademark Office.
[2] The General Hospital Corporation. (2003, July 1). Antidote for opioid overdose (U.S. Patent Application No. 2004/0009923 A1). U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
